zilovertamab vedotin
mAbexperimentalADC
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
8
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2019 (NCT03833180)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Burkitt Lymphoma · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Immunoblastic · Phase 2/Phase 3
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Neuroblastoma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Sarcoma, Ewing · Phase 1/Phase 2
- Stomach Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
Chemistry & pharmacology
- Payload
- Monomethyl auristatin E
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06890884 | Phase 2 | Apr 11, 2025 | Merck |
| NCT06717347 | Phase 3 | Dec 27, 2024 | Merck |
| NCT06395103 | Phase 1/Phase 2 (Phase 2) | Aug 16, 2024 | Merck |
| NCT05562830 | Phase 1/Phase 2 (Phase 2) | Nov 16, 2022 | Merck |
| NCT05458297 | Phase 2 | Jul 21, 2022 | Merck |
| NCT05406401 | Phase 2 | Jul 14, 2022 | Merck |
| NCT05139017 | Phase 2/Phase 3 (Phase 3) | Dec 13, 2021 | Merck |
| NCT05144841 | Phase 2 | Dec 10, 2021 | Merck |
| NCT04504916 | Phase 2 | Oct 16, 2020 | VelosBio |
| NCT03833180 | Phase 1 | Feb 1, 2019 | VelosBio |
Showing 10 of 10 trials
Page 1 / 1